Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment

详细信息    查看全文

• 作者：Forrest C. Jellison (1)
  
  1. Division of Urology ; Pelvic Medicine and Reconstructive Surgery ; Department of Surgery ; Uniformed Services University of the Health Sciences ; 3551 Roger Brooke Dr. ; Fort Sam Houston ; TX ; 78234 ; USA
  
• 关键词：Urinary incontinence ; Overactive bladder ; Neurogenic bladder ; Urodynamics ; Botox ; Neuromodulation
• 刊名：Current Bladder Dysfunction Reports
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：10
• 期：1
• 页码：31-38
• 全文大小：218 KB
• 参考文献：1. Groutz, A, Blaivas, JG, Chaikin, DC, Weiss, JP, Verhaaren, M (2000) The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J Urol 163: pp. 1767-70 47(05)67538-6" target="_blank" title="It opens in new window">CrossRef
  2. Chao, R, Mayo, ME (1995) Incontinence after radical prostatectomy: detrusor or sphincter causes. J Urol 154: pp. 16-8 47(01)67212-4" target="_blank" title="It opens in new window">CrossRef
  3. Elliot, C, Comiter, C (2011) Post-prostatectomy voiding dysfunction. Curr Bladder Dysfunct Rep 6: pp. 211-7 4-011-0103-x" target="_blank" title="It opens in new window">CrossRef
  4. Sanda, MG, Dunn, RL, Michalski, J, Sandler, HM, Northouse, L, Hembroff, L (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358: pp. 1250-61 4311" target="_blank" title="It opens in new window">CrossRef
  5. Tol-Geerdink, JJ, Leer, JW, Oort, IM, Lin, EJ, Weijerman, PC, Vergunst, H (2013) Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer 108: pp. 1784-9 CrossRef
  6. Tekkis, PP, Cornish, JA, Remzi, FH, Tilney, HS, Strong, SA, Church, JM (2009) Measuring sexual and urinary outcomes in women after rectal cancer excision. Dis Colon Rectum 52: pp. 46-54 CrossRef
  7. Wein A, Dmochowski R. Neuromuscular dysfunction of the lower urinary tract. In: Wein, editor. Campbell-Walsh urology. 10th ed. Philadelphia: Elsevier; 2012. p. 1909鈥?6. / A comprehensive review聽that describes neuromuscular lower urinary tract dysfunction and its evaluation and treatment.
  8. Abrams, P, Andersson, KE, Birder, L, Brubaker, L, Cardozo, L, Chapple, C (2010) Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 29: pp. 213-40 CrossRef
  9. Marinkovic, SP, Rovner, ES, Moldwin, RM, Stanton, SL, Gillen, LM, Marinkovic, CM (2012) The management of overactive bladder syndrome. BMJ 344: pp. e2365 CrossRef
  10. Bosch, JL, Norton, P, Jones, JS (2012) Should we screen for and treat lower urinary tract dysfunction after major pelvic surgery? ICI-RS 2011. Neurourol Urodyn 31: pp. 327-9 CrossRef
  11. Gormley, EA, Lightner, DJ, Burgio, KL, Chai, TC, Clemens, JQ, Culkin, DJ (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188: pp. 2455-63 CrossRef
  12. Goode, PS, Burgio, KL, Locher, JL, Umlauf, MG, Lloyd, LK, Roth, DL (2002) Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 50: pp. 808-16 46/j.1532-5415.2002.50204.x" target="_blank" title="It opens in new window">CrossRef
  13. Kurpad, R, Kennelly, MJ (2014) The evaluation and management of refractory neurogenic overactive bladder. Curr Urol Rep 15: pp. 444 4-014-0444-z" target="_blank" title="It opens in new window">CrossRef
  14. Novara, G, Galfano, A, Secco, S, D鈥橢lia, C, Cavalleri, S, Ficarra, V (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54: pp. 740-63 CrossRef
  15. Veenboer, PW, Bosch, JL (2014) Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 191: pp. 1003-8 46" target="_blank" title="It opens in new window">CrossRef
  16. Sears, CL, Lewis, C, Noel, K, Albright, TS, Fischer, JR (2010) Overactive bladder medication adherence when medication is free to patients. J Urol 183: pp. 1077-81 CrossRef
  17. Kanai, A, Zabbarova, I, Oefelein, M, Radziszewski, P, Ikeda, Y, Andersson, KE (2012) Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn 31: pp. 300-8 46" target="_blank" title="It opens in new window">CrossRef
  18. Maman, K, Aballea, S, Nazir, J, Desroziers, K, Neine, ME, Siddiqui, E (2014) Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 65: pp. 755-65 CrossRef
  19. Cui, Y, Zong, H, Yang, C, Yan, H, Zhang, Y (2014) The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 46: pp. 275-84 CrossRef
  20. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2014. / The first phase 2 trial supporting the use of combination therapy, B3-agonists and antimuscarinics, is safe and possibly more efficacious.
  21. Chancellor, M, Levanovich, P, Bharathi, R, Vereecke, A (2014) Optimum management of overactive bladder: medication vs Botox vs InterStim vs Urgent PC. Urol Pract 1: pp. 7-12 4.02.004" target="_blank" title="It opens in new window">CrossRef
  22. Balchandra, P, Rogerson, L (2014) Women鈥檚 perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 25: pp. 1059-64 4-2360-7" target="_blank" title="It opens in new window">CrossRef
  23. Ginsberg, D, Gousse, A, Keppenne, V, Sievert, KD, Thompson, C, Lam, W (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187: pp. 2131-9 CrossRef
  24. Nitti, VW, Dmochowski, R, Herschorn, S, Sand, P, Thompson, C, Nardo, C (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189: pp. 2186-93 CrossRef
  25. Cruz, F, Herschorn, S, Aliotta, P, Brin, M, Thompson, C, Lam, W (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60: pp. 742-50 CrossRef
  26. Vainrib, M, Simma-Chiang, V, Boyd, SD, Ginsberg, DA (2013) Potential risk factors and outcomes of artificial urinary sphincter placement after radical cystectomy and orthotopic neobladder urinary diversion. Neurourol Urodyn 32: pp. 1010-3 45" target="_blank" title="It opens in new window">CrossRef
  27. Mohee, A, Khan, A, Harris, N, Eardley, I (2013) Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 111: pp. 106-13 464-410X.2012.11282.x" target="_blank" title="It opens in new window">CrossRef
  28. Dowson, C, Watkins, J, Khan, MS, Dasgupta, P, Sahai, A (2012) Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 61: pp. 834-9 CrossRef
  29. White, WM, Pickens, RB, Doggweiler, R, Klein, FA (2008) Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 180: pp. 2522-6 CrossRef
  30. Liao, CH, Kuo, HC (2013) Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol 189: pp. 1804-10 CrossRef
  31. Leng, WW, Chancellor, MB (2005) How sacral nerve stimulation neuromodulation works. Urol Clin N Am 32: pp. 11-8 4.09.004" target="_blank" title="It opens in new window">CrossRef
  32. Kessler, TM, Framboise, D, Trelle, S, Fowler, CJ, Kiss, G, Pannek, J (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 58: pp. 865-74 4" target="_blank" title="It opens in new window">CrossRef
  33. Banakhar, MA, Al-Shaiji, T, Hassouna, M (2012) Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem. Ther Adv Urol 4: pp. 179-85 445179" target="_blank" title="It opens in new window">CrossRef
  34. Kerrebroeck, PE, Voskuilen, AC, Heesakkers, JP, Lycklama a Nijholt, AA, Siegel, S, Jonas, U (2007) Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178: pp. 2029-34 CrossRef
  35. Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014. / This study showed the benefit sacral neuromodulation over medications for overactive bladder. This is unlike the ABC and OrBIT study for botox and PTNS which were equivalent to medication.
  36. Jadav, AM, Wadhawan, H, Jones, GL, Wheldon, LW, Radley, SC, Brown, SR (2013) Does sacral nerve stimulation improve global pelvic function in women?. Colorectal Dis Off J Assoc Coloproctol Great Brit Ireland 15: pp. 848-57 CrossRef
  37. Peters, KM, Carrico, DJ, Perez-Marrero, RA, Khan, AU, Wooldridge, LS, Davis, GL (2010) Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 183: pp. 1438-43 CrossRef
  38. Finazzi-Agro, E, Petta, F, Sciobica, F, Pasqualetti, P, Musco, S, Bove, P (2010) Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 184: pp. 2001-6 CrossRef
  39. Zecca, CDG, Robshaw, P, Singh, A, Elneil, S, Gobbi, C (2014) Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol 191: pp. 697-702 CrossRef
  40. Staskin, DR, Peters, KM, MacDiarmid, S, Shore, N, Groat, WC (2012) Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep 13: pp. 327-34 4-012-0274-9" target="_blank" title="It opens in new window">CrossRef
  41. Burton, C, Sajja, A, Latthe, PM (2012) Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 31: pp. 1206-16 CrossRef
  42. Gilbert, SM, Hensle, TW (2005) Metabolic consequences and long-term complications of enterocystoplasty in children: a review. J Urol 173: pp. 1080-6 48.57049.4e" target="_blank" title="It opens in new window">CrossRef
  43. Resnick, MJ, Koyama, T, Fan, KH, Albertsen, PC, Goodman, M, Hamilton, AS (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368: pp. 436-45 CrossRef
  44. D鈥橝mico, AV, Whittington, R, Malkowicz, SB, Schultz, D, Blank, K, Broderick, GA (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: pp. 969-74 CrossRef
  45. Afraa, TA, Campeau, L, Mahfouz, W, Corcos, J (2011) Urodynamic parameters evolution after artificial urinary sphincter implantation for post-radical prostatectomy incontinence with concomitant bladder dysfunction. Can J Urol 18: pp. 5695-8
  46. Giannantoni, A, Mearini, E, Stasi, SM, Mearini, L, Bini, V, Pizzirusso, G (2004) Assessment of bladder and urethral sphincter function before and after radical retropubic prostatectomy. J Urol 171: pp. 1563-6 4390.66" target="_blank" title="It opens in new window">CrossRef
  47. Jura YH, Comiter CV. Urodynamics for postprostatectomy incontinence: when are they helpful and how do we use them? Urol Clin N Am. 2014;41(3):419鈥?7. viii. / A clear and concise review of when UDS testing is appropriate and what etiologies can contribute to LUTD after prostatectomy.
  48. Chung, DB, Kurta, J, Maschino, A, Cronin, A, Sandhu, J (2013) Detrusor underactivity is prevalent after radical prostatectomy: a urodynamic study including risk factors. Can Urol Assoc J 1: pp. E33-7
  49. Liss MA, Morales B, Skarecky D, Ahlering TE. Phase 1 clinical trial of vesicare (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. J Endourol 2014;28(10):1241鈥?.
  50. Siegel, AL (2014) Pelvic floor muscle training in males: practical applications. Urology 84: pp. 1-7 4.03.016" target="_blank" title="It opens in new window">CrossRef
  51. Thiel, DD, Young, PR, Broderick, GA, Heckman, MG, Wehle, MJ, Igel, TC (2007) Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence?. Urology 69: pp. 315-9 CrossRef
  52. Trigo Rocha, F, Gomes, CM, Mitre, AI, Arap, S, Srougi, M (2008) A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. Urology 71: pp. 85-9 CrossRef
  53. Winters, JC, Appell, RA, Rackley, RR (1998) Urodynamic findings in postprostatectomy incontinence. Neurourol Urodyn 17: pp. 493-8 493::AID-NAU5>3.0.CO;2-8" target="_blank" title="It opens in new window">CrossRef
  54. Gelblum, DY, Potters, L, Ashley, R, Waldbaum, R, Wang, XH, Leibel, S (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45: pp. 59-67 CrossRef
  55. Jacobs, SA, Lane, FL, Osann, KE, Noblett, KL (2014) Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn 33: pp. 488-92 437" target="_blank" title="It opens in new window">CrossRef
  56. Jacobs, BL, Smith, RP, Beriwal, S, Benoit, RM (2011) Changes in lower urinary tract symptoms after prostate brachytherapy. J Contemp Brachytherapy 3: pp. 115-20 4/jcb.2011.24816" target="_blank" title="It opens in new window">CrossRef
  57. Ash, D, Bottomley, D, Al-Qaisieh, B, Carey, B, Gould, K, Henry, A (2007) A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 84: pp. 135-9 CrossRef
  58. Merrick, GS, Butler, WM, Wallner, KE, Lief, JH, Galbreath, RW (2002) Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 60: pp. 650-5 4295(02)01840-X" target="_blank" title="It opens in new window">CrossRef
  59. Shimizu N, Minami T, Sugimoto K, Saito Y, Yamamoto Y, Hayashi T, et al. Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol. 2014;32:1423鈥?2.
  60. Boettcher, M, Haselhuhn, A, Jakse, G, Brehmer, B, Kirschner-Hermanns, R (2012) Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?. BJU Int 109: pp. 1824-30 464-410X.2011.10623.x" target="_blank" title="It opens in new window">CrossRef
  61. Bittner, N, Merrick, GS, Brammer, S, Niehaus, A, Wallner, KE, Butler, WM (2008) Role of trospium chloride in brachytherapy-related detrusor overactivity. Urology 71: pp. 460-4 CrossRef
  62. Chou, RH, Wilder, RB, Ji, M, Ryu, JK, Leigh, BR, Earle, JD (2000) Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. Int J Radiat Oncol Biol Phys 47: pp. 115-9 422-3" target="_blank" title="It opens in new window">CrossRef
  63. Cahlon, O, Zelefsky, MJ, Shippy, A, Chan, H, Fuks, Z, Yamada, Y (2008) Ultra-high dose (86.4聽Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71: pp. 330-7 4" target="_blank" title="It opens in new window">CrossRef
  64. Yalla, SV, Andriole, GL (1984) Vesicourethral dysfunction following pelvic visceral ablative surgery. J Urol 132: pp. 503-9
  65. Plotti, F, Angioli, R, Zullo, MA, Sansone, M, Altavilla, T, Antonelli, E (2011) Update on urodynamic bladder dysfunctions after radical hysterectomy for cervical cancer. Crit Rev Oncol Hematol 80: pp. 323-9 4" target="_blank" title="It opens in new window">CrossRef
  66. Nesbakken, A, Nygaard, K, Bull-Njaa, T, Carlsen, E, Eri, LM (2000) Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg 87: pp. 206-10 46/j.1365-2168.2000.01357.x" target="_blank" title="It opens in new window">CrossRef
  67. Havenga, K, Enker, WE, McDermott, K, Cohen, AM, Minsky, BD, Guillem, J (1996) Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 182: pp. 495-502
  68. Lee, DK, Jo, MK, Song, K, Park, JW, Moon, SM (2010) Voiding and sexual function after autonomic-nerve-preserving surgery for rectal cancer in disease-free male patients. Korean J Urol 51: pp. 858-62 4111/kju.2010.51.12.858" target="_blank" title="It opens in new window">CrossRef
  69. Katepratoom, C, Manchana, T, Amornwichet, N (2014) Lower urinary tract dysfunction and quality of life in cervical cancer survivors after concurrent chemoradiation versus radical hysterectomy. Int Urogynecol J 25: pp. 91-6 CrossRef
  
• 刊物主题：Urology/Andrology;
• 出版者：Springer US
• ISSN：1931-7220

文摘

Overactive bladder (OAB) syndrome is a common condition associated with a lower quality of life. It poses a significant health burden to patients and cost to the health care system. The etiology of OAB symptoms after cancer treatment may be idiopathic or neurogenic. Pelvic surgery and radiation are associated with neurogenic changes that can cause OAB symptoms. Comprehensive evaluation is indicated in this high-risk group. Management of OAB symptoms is patient centered with a focus on initiating therapy with the fewest side effects that are reversible. Behavioral, medical therapy, botulinum injections, sacral neuromodulation (SNM), percutaneous tibial nerve stimulation (PTNS), and urinary reconstruction will be discussed. An in-depth discussion about each of the treatment options will assist in selecting the optimal treatment.